A 28-year-old man with a known history of hereditary hemolytic anemia due to glucose-6-phosphate dehydrogenase (G6PD) deficiency is admitted with acute hemolytic crisis triggered by sulfonamide exposure. To assess the severity of hemolysis and confirm G6PD deficiency as the underlying cause, which investigation is most appropriate during the acute phase?

Explanation

## Diagnostic Approach to G6PD Deficiency in Acute Hemolytic Crisis ### Clinical Context This patient presents with acute hemolytic crisis triggered by oxidative stress (sulfonamide). The question asks for the **most appropriate investigation during the acute phase** — a critical distinction, as the timing of testing affects interpretation. ### Why Reticulocyte Count and Peripheral Blood Smear Are Optimal **Key Point:** During acute hemolysis, reticulocyte count and peripheral blood smear are the most appropriate investigations because they: 1. **Assess hemolysis severity in real-time** — reticulocyte count rises dramatically (>10%) within 24–48 hours of hemolysis onset 2. **Identify hemolytic markers** — schistocytes, spherocytes, bite cells (pathognomonic for G6PD), polychromasia 3. **Guide immediate management** — elevated reticulocytes indicate bone marrow response; severity guides transfusion decisions 4. **Are immediately available** — no delay in diagnosis or treatment ### Critical Timing Issue: G6PD Enzyme Assay in Acute Phase **Warning:** Serum G6PD enzyme activity assay is **NOT reliable during acute hemolysis** because: - Young RBCs (reticulocytes) have higher G6PD activity than mature RBCs - During acute hemolysis, older, enzyme-deficient RBCs are destroyed first - Reticulocytosis falsely elevates measured G6PD activity, causing false-negative results - **Enzyme assay must be deferred 3–4 weeks after hemolytic crisis resolves** for accurate diagnosis ### Comparison of Investigations | Investigation | Acute Phase Utility | Timing | |---|---|---| | **Reticulocyte count & blood smear** | Excellent — confirms hemolysis, shows bite cells | Immediate, real-time | | **G6PD enzyme assay** | Poor — falsely elevated due to reticulocytosis | Defer 3–4 weeks post-crisis | | **Hemoglobin electrophoresis** | Not useful for G6PD; rules out hemoglobinopathy | Not indicated here | | **Haptoglobin level** | Supportive — low/absent in hemolysis | Useful but non-specific | | **Urine hemoglobin & indirect bilirubin** | Supportive — confirms intravascular hemolysis | Useful but non-specific | **High-Yield:** Bite cells (RBCs with a "bitten" appearance from Heinz body removal by spleen) are **pathognomonic for G6PD deficiency** and are best seen on peripheral blood smear during acute hemolysis. **Mnemonic:** **CRISIS** in G6PD hemolysis: - **C**ells destroyed (reticulocytosis ↑) - **R**eticulocytes elevated (>10%) - **I**ndirect bilirubin ↑ - **S**pherocytes and schistocytes on smear - **I**ntravascular hemolysis (hemoglobinuria) - **S**evere if untreated ### Diagnostic Algorithm for G6PD Deficiency ```mermaid flowchart TD A[Acute hemolytic crisis + oxidative trigger]:::outcome A --> B[Reticulocyte count & blood smear]:::action B --> C{Bite cells present?}:::decision C -->|Yes| D[Strongly suggests G6PD]:::outcome C -->|No| E[Consider other hemolytic causes]:::outcome D --> F[Defer enzyme assay 3-4 weeks]:::action F --> G[G6PD enzyme activity assay]:::action G --> H{Activity low?}:::decision H -->|Yes| I[G6PD deficiency confirmed]:::outcome H -->|No| J[Consider variant G6PD or other cause]:::outcome ``` **Clinical Pearl:** G6PD deficiency is the most common enzyme deficiency worldwide (>400 million affected); X-linked inheritance explains male predominance and variable female carrier expression.